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Multistage models of carcinogenesis proposed to account for the observed patterns of tumor devel-
opment in the skin, liver, lung, bladder and other organs involve initiation of neoplastic change in a
few cells by a threshold dose of carcinogen followed by conversion of these latent tumor cells into
an autonomous cancer by further doses of the same and/or other carcinogens, and/or noncarcino-
genic promoting agents. In the rat urinary bladder, neoplastic change can be initiated by a few
weeks treatment with low doses of N-butyl-N-4-hydroxybutyl)nitrosamine (BBN) or N-[445-nitro-2-
furyl-2-thiazolyl]formamide (FANFT) or by a single, low dose, intravesicular instillation of
N-methyl-N-nitrosourea (MNU). Very few animals treated thus will develop bladder cancer unless ex-
posed subsequently to some further regime which will promote tumor growth from the initiated
cells.
Many different factors will stimulate tumor growth in the initiated rat bladder, including further
low doses of complete bladder carcinogens, dietary factors such as metabolites of tryptophan or de-
ficiency of vitamin A, the food additives saccharin and cyclamate and some alkylating agents such
as cyclophosphamide and methylmethane sulfonate. New and published evidence is reviewed which
supports the belief that these and other factors are promoters or later stage carcinogens in the blad-
der. The difficulties of defining a promoter and of identifying markers of promotion, i.e., of distin-
guishing the second from the later stages of carcinogenesis in the urinary bladder, are discussed
with reference to the action of promoters in the mouse skin initiation/promotion model. However, in
terms of their effect on an initiated population on the risk of developing cancer, it is suggested that
such a distinction is largely irrelevant. Since both second and later stage carcinogens accelerate tu-
mor development in an initiated urothelium, they both have the potential to lower the age at which
bladder cancer becomes symptomatic. They are thus as important as are initiating carcinogens in
determining the patterns of age-related neoplastic disease in any population.
Introduction
Multistage models of carcinogenesis have been
proposed to account for the observed patterns of tu-
mor development in the skin, liver, lung, bladder
and other organs (1-10). Such models involve initia-
tion of neoplastic change in a few cells by a thresh-
old dose of carcinogen, followed by conversion of
these initiated tumor cells into an autonomous can-
cer by further doses of the same and/or other car-
cinogens, and/or noncarcinogenic promoting agents.
In the rat urinary bladder, neoplastic change can
be initiated by a few weeks treatment with low
doses of N-butyl-N-4-hydroxybutyl)nitrosamine
(BBN) (11, 12) or N-[445-nitro-2-furyl)2-thiazolyl]
formamide (FANFT) (13, 14) or by a single, low dose,
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intravesicular instillation of N-methyl-N-nitrosourea
(MNU) (15, 16). Very few of the animals treated with
an initiating dose of such a carcinogen will develop
bladder cancer in their natural lifespan unless they
are exposed subsequently to some further regime
which will promote tumor growth from the initiated
tumor cells. The initiating event is generally be-
lieved to be rapid and to involve an interaction of
the initiating carcinogen with the DNA of the tar-
get cell to produce a permanent mutagenic event (2,
17). By contrast, promoting agents do not necessar-
ily interact with the DNA and thus are not neces-
sarily mutagens; promotion is thought to involve
epigenetic as opposed to genetic events (18). Fur-
thermore, prolonged or repeated exposure of the
initiated cell to promoters is required to achieve tu-
mor growth (2).
The concept of tumor promotion was developedfrom studies on the mouse skin model by using the
diterpene series of promoters present in croton oil
(1, 2, 4, 19, 20). The extension of this concept to any
other tissue has become partly a problem of seman-
tics, i.e., the study of the meaning of the word as
well as its original derivation. It was realized only
recently that the mechanism of carcinogenesis in
other epithelial tissues has much in common with
carcinogenesis in the mouse skin, even though other
carcinogens and other promoters are involved, but
it is not yet clear if every observation made with
the mouse skin model can be rigidly applied to
other tissues. For example, from studies with the
polycyclic hydrocarbon class of carcinogens in the
mouse skin it was concluded that initiation is a
rapid, "permanent" event which will persist more or
less indefinitely; initiated cells can thus remain dor-
mant but still be susceptible to promotion many
months after the initiating event (2). This may well
prove to be substantially true not only for the skin
but also for other tissues and other carcinogens, but
the rigid concept of permanence may yet have to be
modified to take into account the well recognized
fact that much potentially initiating carcinogen-in-
duced DNA damage is in fact not permanent, but is
eliminated by enzymatic repair mechanisms'(21).
Whether or not the initiating damage is permanent
may depend on the carcinogen and the exact nature
of the interaction between it and the genome. Thus
in the bladder, there appears to be a considerable
decay in the number of persisting initiated cells in
the first 6 weeks following treatment with initiating
doses of FANFT (14) whereas, by contrast, the initi-
ating effect of MNU does persist undiminished for
at least 25 weeks (16, 22).
If promotion is to be strictly defined by reference
to the mouse skin model, then only compounds
equivalent to 12-0-tetradecanoylphorbol-13-acetate
(TPA) which bring about the second stage in a mul-
tistage process can be considered, and any factors
such as ethylphenylpropriolate which act at the
third or later stages in carcinogenesis must be ex-
cluded from the discussion. The argument is further
confused, however, for recently incomplete first-
and second-stage promoters have been defined; for
example the calcium ionophore A23187 is a first-
stage promoter and mezerein a second-stage pro-
moter in skin carcinogenesis (23). When attempting
to define the biochemical and cellular mechanisms
which underlie early stages of tumor growth, a nar-
row definition of promotion in terms of biochemical
and biological events is clearly essential. In terms of
human disease, however, if continuous exposure to
a factor increases the risk of developing a particular
cancer and conversely, if removal of that factor de-
creases the risk, it is largely irrelevant whether the
agent happens to act predominantly at the second
stage, i.e., as a promoter, or at one of the later
stages in the carcinogenic process.
Complete carcinogens can bring about all stages
of the carcinogenic process if a sufficient dose is
given over a long enough period of time, i.e., they
act both as initiators, promoters and later stage car-
cinogens. However, not all complete carcinogens are
necessarily equally effective at the different stages
of carcinogenesis and, indeed, there is no a priori
reason why they should be, for the biochemical
events underlying the initiation and later stages of
carcinogenesis differ quite fundamentally. Some car-
cinogens are more effective at the first, initiating
stage but are poor promoters, for example 2-acetyl-
aminofluorene (2-AAF) in its effect on the rat liver
(24), whereas other carcinogens or the same carcino-
gen in other tissues, may be weak initiators but
powerful late stage carcinogens, for example 2-AAF
in the rat bladder (25). Thus many compounds pos-
sess a spectrum of carcinogenic activity, and it is
rare to find a compound which is a "pure" initiator
or one which is a "pure" promoter. Many agents
generally regarded as promoters, e.g., croton oil,
also have some, albeit weak, initiating activity
(26-28).
Factors Identified as Affecting the
Second Stage (Promotion) and/or
Later Stages of Carcinogenesis in
the Urinary Bladder
In models other than the mouse skin, very few
late-stage carcinogens have been investigated in
sufficient detail to say whether they meet all the
criteria which have been defined for a promoter in
skin. In experimental rat bladder models a number
of compounds have been identified which signifi-
cantly increase the tumor incidence after treatment
with an initiating dose of carcinogen. Of these, so-
dium cyclamate after MNU (29), sodium saccharin
after MNU (16, 29), after FANFT (14) or after BBN
(30, 31) tryptophan after FANFT in the rat and
mouse bladder (14, 32) and after 4-aminobiphenyl
and 2-naphthylamine in the dog (33) and phenacetin
after BBN (12), can all be claimed to act as late-stage
carcinogens and possibly as promoters for the de-
velopment of transitional cell carcinoma in a previ-
ously initiated urothelium. The evidence for re-
garding these chemicals as promoters in the urinary
bladder is already published and is primarily based
on their ability to increase the tumor yield above
that produced by an initiating dose of carcinogen
alone. On the published evidence they may well act
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as second-stage rather than later-stage carcinogens,
but the data are far from unequivocal (34).
Other factors which also increase the time-related
tumor yield in carcinogen-treated bladders include
an as yet unidentified component of normal rat
urine (35-39), presence of the male sex hormone,
testosterone (40, 41), deficiency of vitamin A (42) and
nonspecific irritation of the bladder mucosa either
by a calculus (35) or by calcified and/or live ova of
the parasite Schistosoma haematobium (43).
The effect of S.haematobium infection is inter-
esting as it illustrates the effect that irritation can
have on the induction of bladder cancer. In experi-
mental animals, egg deposition which occurs in the
bladder during S.haematobium infections in general
leads to extensive inflammation followed by fibrosis
of the bladder wall, polyp formation, and ulceration
plus hyperplasia of the urothelium, but urothelial
carcinoma does not usually follow simple infection
with S. haematobium alone. [Well differentiated,
papillary carcinomas were reported in one Capuchin
and one Talapoin monkey and in the ureter of one
of 21 baboons infected with S.haematobium (44), but
subsequent experiments showed that similar lesions
in Capuchin monkeys had a restricted growth po-
tential and did not survive transplantation; further-
more the primaries regressed in the third or fourth
year after infection (45).] In our study, in addition to
infecting animals with Shaematobium cercariae,
weekly low doses of BBN were used to give a
threshold carcinogenic stimulus to the urothelium
(43).
None of the five baboons given BBN alone devel-
oped neoplastic urothelial lesions in the 21/2-year ex-
periment nor did those treated with S.haematobium
alone, although the latter group developed various
degrees of urothelial hyperplasia. Of the 10 animals
treated both with BBN and S.haematobium, four de-
veloped neoplastic disease of the bladder (Fig. 1)
and three had multiple endophytic papillary down-
growths of the urothelium into the walls of the ure-
ters which passed into and through the muscle lay-
ers (Fig. 2). Although the BBN treatment alone was
subcarcinogenic in the 21/2 years duration of this ex-
periment, this period represents only a quarter or
less of the normal lifespan of this species and it
FIGURE 1. Adenocarcinoma of the urothelium in a baboon treated with 5 mg BBN/kg/week and infected with S.haematobium,
killed 21/2 years after infection. Neoplastic downgrowths of urothelium have penetrated deeply into the lamina propria and
into the superficial muscle layer of the bladder wall. Wax-embedded; H & E; x 100.
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FIGURE 2. Downgrowth of dysplastic urothelium which has penetrated the circular muscle layers in one ureter of a baboon
treated as the animal illustrated in Fig. 1 with BBN and infected with S.haematobium. Epon-embedded; Toluidine Blue; x
200.
would be rash to conclude that the monkey is im-
mune to BBN. This bladder carcinogen is effective
in several other species (40, 46-48) and would doubt-
less have proved so in the baboons if the animals
had been kept alive for a further 10 years or so. The
S.haematobium infection probably acted by re-
ducing the latent period before tumor growth com-
menced, thus bringing forward the time at which
urothelial carcinoma developed to within the time
scale of the experiment. In all probability, the "pro-
moting" effect ofShaematobium in this system is in
fact a propagating stimulus attributable to in-
creased urothelial cell turnover in response to me-
chanical irritation. We suggest that the primary ef-
fect of S.haematobium in the induction of bilharzial
bladder cancer in countries such as Egypt, is to
lower the age-related cancer incidence following ex-
posure to some as yet unidentified initiating carcino-
gen, by acting at a late state in the carcinogenic pro-
cess. In the West, the peak age of bladder cancer in-
cidence is in the seventh decade, whereas in Egypt
it is in the fifth decade. The effect on the bladder of
calculi, an indwelling catheter, or any other local ir-
ritant could well act in the same way and lower the
age at which bladder cancer becomes symptomatic
in any particular individual.
Another compound which may be added to this
list of late stage carcinogens or promoters of car-
cinogenesis in the bladder is methylmethane sul-
fonate (MMS). MMS has been reported to produce
tumors of the nervous system in rats after IP in-
jection (49) and local tumors after subcutaneous in-
jection (50). We have investigated its ability to act
both as a complete carcinogen and as a promoting
agent when applied directly to the urothelium in
our MNU/rat model. For the present work an in-
bred strain, the F344 rat was used instead of the
outbred Wistars used for previous experiments
with the MNU/bladder model. Animals were given
six intravesicular doses of 2.5 mg MMS either alone,
or following a single threshold/initiating intravesic-
ular dose of 0.3 mg MNU. Appropriate untreated
controls and a control group given the 0.3 mg MNU
only were set up in parallel, and the number of mac-
roscopically visible tumors produced in 2 years is
show in Table 1. The final number of neoplasms
Table 1. Promotion of methylnitrosourea(MNU)-induced
bladder cancer with methylmethane Sulfonate (MMS) in
female F344 rats.
Treatment Number of Number of Incidence of
(intravesicular instillation) animals tumorsa tumors,%
1 x 0.3 mgMNU 30 7 23
6 x 2.5mg.MMS 32 2 6
1 x 0.3 mg MNU plus
6 x 2.5mgMMS 37 18 49
Untreated controls 27 0 0
aMacroscopic observations; preliminary data from un-
published observations by R. J. Tudor, R. M. Hicks, N.
Severs, and S. Barnes.
40PROMOTERS AND INCIDENCE OF BLADDER CANCER
may be modified after completion of histological
examination of serial sections of all bladders, but
these preliminary results are included here, since
they demonstrate for the first time that this
compound also behaves as a very weak bladder car-
cinogen when used on its own, and as an effective
promoting agent when applied to a previously initi-
ated urothelium. This suggests that MMS, like 2-
AAF, has weak first stage but powerful late stage
carcinogenic potential for the bladder urothelium.
Another compound which we believe falls into
this category is cyclophosphamide. As reported pre-
viously, 18 single IP doses given at monthly inter-
vals (total dose 1800 mg/kg body weight over 11/2
years) failed to produce bladder cancer (29). Simi-
larly, 10 mg/kg body weight twice weekly for 40
weeks (total dose 800 mg/kg body weight) was not
carcinogenic on its own but did produce a 35% inci-
dence of bladder cancer following a 6-week course of
a threshold dose of FANFT (51). When, however,
rats were given lifetime treatment with cyclophos-
phamide by including it in the drinking water five
times a week to give total doses of 1,270, 698, 475
and 230 mg/kg body weight, a low dose-related inci-
dence of bladder cancer was obtained in male rats
(52). At the highest dose level, seven of 37 (19%)
males but only one of 35 females developed bladder
cancer. No bladder cancers were found in the three
groups of females given the lower doses of cyclo-
phosphamide, but 13%, 5% and 5%, respectively, of
the males developed transitional cell carcinoma.
These results are consistent with the suggestion
that cyclophosphamide, like 2-AAF and MMS, is a
weak first-stage carcinogen but a more effective
promoter or late-stage carcinogen. These obser-
vations have obvious clinical implications when it is
remembered that cyclophosphamide is frequently
used as only one of several agents, some of which
are mutagenic, in a combined cytotoxic therapy re-
gime for treating neoplastic disease elsewhere in
the body.
In general, such factors as vitamin A deficiency,
S.haematobium infection, etc. have not been re-
garded by their investigators as promoters, but
rather as late stage carcinogens comparable to tur-
pentine or ethylphenylpropriolate in the mouse skin
model, although urine has been referred to as a tu-
mor promoter (38, 39). There may or may not prove
to be a sound basis for making a distinction be-
tween the first group ofcompounds discussed above
such as saccharin, tryptophan, etc., as promoting
factors, and the second group, calculi, vitamin A de-
ficiency etc., as later-stage carcinogens, but as yet
the experimental evidence is insufficient for this dis-
tinction to be regarded as unequivocal.
Biological Markers of Promotion
In the Mouse Skin
Numerous biochemical and biological phenomena
have been investigated as markers of promotion in
the mouse skin following application of TPA. Those
which appear to correlate well with promotion in-
clude the induction of the enzyme ornithine decar-
boxylase (ODC) and a consequent increase in poly-
amine synthesis, the induction of hyperplasia and of
dark basal keratinocytes, the inhibition of normal
tissue differentiation and alteration in the normal
pattern of gene expession (17, 18, 53-57).
None of these phenomena, however, are unique
markers for promoters. Thus although all skin pro-
moters are hyperplastic agents, the converse is not
true. Similarly, growth promoting stimuli in general
will induce ODC and polyamines. For example, par-
tial hepatectomy (58, 59), isoproterenol in the sali-
vary gland (60), growth-promoting hormones (61-63)
and epidermal growth factor (64) will all stimulate
ODC and polyamine synthesis in their target tis-
sues. The induction of ODC is probably a marker for
cell proliferation rather than for second stage carci-
nogenesis. Since factors which stimulate cell prolif-
eration also accelerate tumor growth, it is likely to
be associated with the later stages ofcarcinogenesis
rather than with the second stage exclusively.
Currently much emphasis is being placed on the
ability of TPA but not of the later stage "promoter"
mezerein, to induce the appearance of large num-
bers of dark, basal keratinocytes in skin (18). These
dark keratinocytes are also induced by the incom-
plete promoter, the calcium ionophore A23187 (23).
However, these results were obtained in a mouse
strain, the Sencar, which is peculiarly sensitive to
TPA promotion and they may or may not hold for
other strains or other species. Slaga and his col-
leagues have suggested that dark keratinocytes
may be primitive stem cells since they are also
found in large numbers in embryonic and new born
mouse skin (53, 54). Dark cells are also found in pap-
illomas and carcinomas (53, 54) and must therefore
be induced by complete carcinogens as well as by
TPA.
Many published studies demonstrate that the di-
terpene series of promoters delay or prevent ter-
minal differentiation of cell lines in culture. They
increase the time, i.e., the number of cell divisions
required before a cell can leave the cell cycle and
enter the pathway for terminal differentiation and
subsequent death. In vivo, if the basal stem cells of
epithelial tissues are affected by a promoter in this
way, then after each cell division the daughter cells
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will be recruited, even if only temporarily, to the di-
viding stem cell population, the tissue will become
hyperplastic and fail to differentiate normally, and
the predominant cell population will appear rela-
tively undifferentiated. If in addition, the original
stem cells had been previously subjected to an initi-
ating event, the new increased cell population will
carry this defect in their genome and the chances of
it being expressed as a new phenotype automati-
cally will be greater than in a smaller cell popula-
tion.
Although supression of terminal differentiation
has been regarded as a characteristic property of
promoters, recently evidence has been published
which demonstrates that many mouse skin cells be-
come resistant to terminal differentiation after ex-
posure in vivo to an initiating dose of carcinogen
(65). Thus the regulation of normal differentiation, in
particular the development of the proliferative
block which permits terminal differentiation, may
be disturbed primarily by the initiating event and
not by promotion, although in vivo the cell division
which accompanies promotion may be a necessary
factor before the failure to differentiate is made evi-
dent.
One of the significant properties of promoters is
thought to be their ability to alter the normal pat-
tern of gene expression, thereby permitting expres-
sion of normally repressed areas of the genome
with the consequent appearance of new phenotypes
(17). At the same time this increases the chance of
expression of any latent initiating damage to the
DNA which may have occurred in an area of the ge-
nome not normally expressed in that particular cell
type. This disturbance of gene expression is re-
flected in the bizarre metaplasias seen in many tu-
mors and has given rise to the concept of cancer as
a disease of maladjusted differentiation. Many of
the "new" phenotypes seen in cancers have accord-
ingly been claimed as markers of neoplastic trans-
formation, whereas in fact, they are more often epi-
phenomena and not causally implicated in the devel-
opment of neoplastic growth.
At present, even in the mouse skin there is thus
no single specific marker for a second-stage carcino-
gen (promoter) which will distinguish it unequivo-
cally from a complete or later-stage carcinogen,
other than its ability or inability to function at a
particular point in a strictly defined temporal se-
quence in a multistage process of carcinogenesis.
In the Rat Urinary Bladder
As a model for the study of multistage carcino-
genesis, the rat bladder has been developed far
more recently (14, 29, 30, 66) than was the mouse
skin model (1), and the direct effects of promoters
and other late-stage carcinogens on the urothelium
have been less systematically studied than they
have in skin. Such studies as have been made show
considerable similarity between the rat bladder and
the mouse skin models.
Inducton ofODC Direct application to the uro-
thelium by intravesicular instillation of the com-
plete carcinogen FANFT or its major urinary me-
tabolite, 2-amino-445-nitro-2-furyl)2-thiazolyl (ANFT)
causes a rapid induction of ODC; similarly ODC ac-
tivity in the urothelium was induced by FANFT ad-
ministration PO (67). These results indicate that the
urothelium, like skin, may be expected to react to
treatment with other complete carcinogens by an
induction of ODC which appears at the time of cell
proliferation in the neoplastic tissue. To some ex-
tent this has been confirmed using three urothelial
cells lines derived from rat bladder carcinomas.
When these cancer cells were treated in vitro with
the bladder carcinogens MNU, ANFT, or N-butyl-(3-
carboxypropyl)nitrosamine (BCPN), ODC was in-
duced (68). ODC was induced in this system to a sim-
ilar extent by the second or later stage carcinogen
saccharin and by 3-hydroxyanthranilic acid, a
metabolite of 3-tryptophan. Epidermal growth fac-
tor (EGF) and insulin also induced ODC; but no
aforementioned inducer was anywhere near as ef-
fective as was TPA (68). On the basis of these
results, ODC induction appears to be concomitant
with tumor promotion in the bladder as well as in
the skin and furthermore TPA may well prove to
be an effective promoter of carcinogenesis in the
urothelium. With the in vitro cancer cell culture sys-
tem, ODC was also shown to be inducible by an uni-
dentified, heat-stable, filterable factor in rat urine
which the authors related to previous reports of
promoting activity in rat urine (36-38).
Induction of UrothelialHyperplasia. Many of the
agents identified as second- or later-stage carcino-
gens for the bladder also have the ability to induce
urothelial hyperplasia when used on their own.
Thus mechanical irritation from bladder calculi and
from S.haematobium ova has been widely reported
to cause local regenerative hyperplasia. Similarly,
vitamin A deficiency causes an increased mitotic ac-
tivity in the basal cells of the urothelium leading to
hyperplasia and ultimately to epidermalization (67,
70, 71). High concentrations of dietary saccharin
cause focal hyperplasia of the urothelium with in-
creased numbers of cells entering into mitosis (72).
Contrary to a previous report (14), this was later
confirmed by Fukushima and Cohen (73), who ob-
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served an increased uptake of tritiated thymidine
into focal areas of the bladder urothelium in sac-
charin-treated rats. Urine, as well as promoting
tumor growth, also induces hyperplasia in the
urothelium of heterotopically transplanted rat
bladders (74). However, since urine does not cause
hyperplasia in the normal bladder in situ, the ex-
planation for its hyperplastic effect on heterotopic
bladders is not necessarily related to its tumor-
promoting potential.
Cyclophosphamide has long been known to pro-
duce severe atypical hyperplasia following cytotoxic
damage to the urothelium (75-77). MMS (78) and 2-
AAF (25) likewise produce urothelial hyperplasia.
As discussed above, these last three compounds are
also weak complete carcinogens and after prolonged
application will produce cancer of the urothelium,
but their hyperplastic action is probably associated
with their late-stage carcinogenic activity rather
than with their first stage initiating activity.
Induction of Dark Basal Cells Dark basal cells,
comparable to those reported by Slaga et al. (18), in
embryonic and promoted skin and in skin cancers
are a feature of neoplastic rat urothelium treated
with complete carcinogens such as BBN, FANFT,
MNU (Fig. 3), and 2-naphthylamine (Fig. 4). They are
seen in both papillary (Fig. 5) and nodular tumors
and in areas of atypical but not necessarily hyper-
plastic urothelium within 2 weeks of completing a
carcinogenic treatment with MNU (Fig. 3). They are
also present in small numbers in the human fetal
bladder (Fig. 6). A few dark basal cells are occasion-
ally found in normal, adult, untreated rat urothe-
lium particularly in females, but they do not appear
to be significantly increased in number by pro-
longed treatment of the animal with saccharin.
They are present in some saccharin-treated animals
(72), but not with sufficient regularity to be treat-
ment-related. Dark cells are also seen in association
with squamous metaplasia in vitamin A-deficient
rats, and in that situation they reflect increased
numbers of tonofilaments and ribosomes in the
keratinising tissue. We have not yet observed dark
basal cells in areas of simple urothelial hyperplasia
induced by treatment with MMS alone or cyclophos-
phamide alone although there were dark basal cells
in transitional cell tumors induced by MMS only.
The effect of 2-AAF on the staining characteristics
of the basal urothelial cell layer does not appear to
have been reported. At the moment, therefore,
there is no positive evidence to suggest that the in-
duction of dark basal cells can be regarded as a
3
FIGURE 3. Dark basal cells in an area of flat, dysplastic urothelium lining the bladder of a rat 2 weeks after completing a fully
carcinogenic course of MNU (four doses, 1.5 mg each). Epon-embedded; Toluidine Blue; x 800.
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FIGURE 4. Darkly staining basal cells in the mildly hyperplastic and dysplastic urothelium lining the bladder of a rat treated
with 2-naphthylamine (300 mg/kg/week for 57 weeks). Epon-embedded; Toluidine Blue; x 800.
FIGURE 5. Dark basal cells in the urothelium of a papillary transitional cell carcinoma of the rat bladder, induced by MNU. Epon-
embedded; Toluidine Blue; x 350.
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FIGURE 6. Part of a section through the bladder of a 17 week human fetus. The urothelium is composed of two to three layers of
roughly cuboidal cells some ofwhich, both in the basal and superficial layers, have darkly staining cytoplasm. Epon-embedded;
Toluidine Blue; x 600.
marker for promotion rather than for any other
stage of carcinogenesis in the urinary bladder, but
since there has been no systematic attempt to cor-
relate dark cells with promotion in this tissue, this
conclusion may have to be revised in the light of
further work.
Inhibition of Normal Differentiation and the Pro-
duction of Atypical Phenotype& In saccharin-in-
duced hyperplasias there is a failure of terminal dif-
ferentiation but we did not observe any metaplasias
in our saccharin-treated rats. By contrast, rat blad-
der tumors produced by initiation with MNU fol-
lowed by promotion with saccharin exhibited a wide
variety of differentiation patterns both within the
tumor and in adjacent, non-neoplastic areas of the
urothelium (6, 79). This may reflect the ability of sac-
charin to increase the change of random transcrip-
tion of the genome.
Adequate supplies of vitamin A have long been
known to be essential for the normal differentiation
of epithelial tissues including the urothelium. Vita-
min A deficiency alone leads first to hyperplasia of
the urothelium in which the normal differentiation
of the tissue is suppressed, and then to epider-
malisation with formation of a stratum granulosum
containing keratohyalin granules and a keratinized
horny layer (70, 71). These same changes were also
reported in bladder cancer induced with methylcho-
lanthrene as the initiating carcinogen in vitamin A-
deficient animals (42). In this situation, squamous
metaplasia is not indicative of neoplastic transfor-
mation or promotion per se, but is the consequence
of the direct effect of vitamin A deficiency on gene
expression.
In female rats, the addition of testosterone alone
has no effect on the differentiation of the urothe-
lium, but if the animals have been pretreated with
BBN, testosterone increases the incidence of hyper-
plasias, cancers and of squamous metaplasias (41).
Squamous metaplasias were found in a significant
number of bladder tumors in 2-AAF-treated mice
(80). In our MMS-treated animals, the two tumors in-
duced by multiple doses of MMS alone both had
areas of squamous metaplasia, but no metaplasias
were seen in other animals with hyperplastic uro-
thelia but no tumors. Cyclophosphamide causes first
cytotoxic damage and strips the urothelium from
the basal lamina, but the subsequent hyperplasias
are both undifferentiated and dysplastic. Fur-
thermore, the normal progression from diploid
basal, through tetraploid intermediate to octaploid
or hyperploid superficial cells which are characteris-
tic of the normal urothelium (15), is disrupted by cy-
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clophosphamide, and temporarily there is aneu-
ploidy with many hyperpolyploid nuclei (81).
Irritation of the bladder mucosa frequently leads
to squamous metaplasia of the urothelium. This may
be seen following irritation by a calculus or in man
from other sources of local irritation such as an in-
dwelling catheter or chronic bacterial cystitis, all of
which provide a proliferative stimulus to the uro-
thelium. If the urothelium in addition has previously
undergone neoplastic transformation, such local irri-
tation will accelerate the development of urothelial
tumors and at the same time predispose to focal
areas of squamous metaplasia. An example of this in
man is the development of bilharzial bladder cancer,
in which squamous cell carcinoma is the predomi-
nant type. Interestingly, irritation of the urothelium
does not always result in squamous metaplasia but
alternatively may produce mucous metaplasia. For
example, cystitis cystica with mucous metaplasia
developed in our S.haematobium-infected baboons,
and in those animals receiving additionally an initi-
ating does of BBN, both mucous metaplasias and
adenocarcinomas were found. Unlike the response
of the human urothelium to S.haematobium infec-
tion, none of these infected baboons developed squa-
mous cell carcinoma of the urothelium. It seems
probable that both mucous and squamous metapla-
sia are alternative phenotypes to the transitional
cell phenotype normally found in the urothelium,
which are relatively easily induced and expressed in
the rapidly proliferating tissue, and that neither
should be regarded automatically as a pre-malig-
nant condition or even as a marker of promotion.
The development of long and/or pleiomorphic mi-
crovilli on the urinary face of cells in carcinogen-
treated bladders, for some time has been thought to
represent the fortuitous expression of a new pheno-
type which appeared to be a convenient marker for
neoplastic transformation in the bladder (6, 13, 79,
82-84). More recently, such microvilli have been ob-
served on urothelial cells after treatment with
either saccharin alone (73) or with cyclophospha-
mide alone (85), which suggested they might be as-
sociated with the later stages, rather than the initia-
tion of carcinogenesis in this tissue. However, they
have now been observed after treatment of the
bladder with formalin, and after wounding the uro-
thelium by surgery or freezing (86). All these treat-
ments produced reversible regenerative hyperpla-
sia of the urothelium and the appearance of the
microvilli coincided with the time of maximum cell
proliferation. Thus, the production of microvilli in a
carcinogen-treated bladder, like the induction of
ODC in skin, is an epiphenomenon and a marker for
cell proliferation rather than a specific marker for
neoplastic transformation or promotion of tumor
growth.
Conclusions
The evidence is overwhelming that in experimen-
tal animal models carcinogenesis in the bladder is a
multistage process involving both early initiating
and later promoting and/or subsequent events (10,
34). As Doll and Peto (87) point out, if cells have to
experience both early and late events before cancer
can develop, then elimination of exposure to either
early or later carcinogens will reduce the eventual
risk of cancer, and the only determinant of which is
the more "important" is which is more easily
avoided. The distinction between early and late
stage carcinogens, however, is far more than just
academic. There is a marked difference between the
effect of terminating exposure to a predominantly
first-stage carcinogen and the effect of terminating
exposure to a promoting or later-stage carcinogen,
as is shown both with experimental rat models and
human epidemiological data (9). Because, in general,
first-stage initiating carcinogens are also complete
carcinogens, even after exposure is terminated the
incidence of tumors continues to increase with time,
as evidenced in rats by the increasing risk of liver
cancer after terminating exposure to 2-AAF (24) and
in the human population by the continued rise of 2-
naphthylamine-induced bladder cancer long after
exposure to this chemical was dicontinued (88). By
contrast, when exposure to a predominantly later-
stage carcinogen is discontinued, the relative risk of
developing cancer does not rise further but either
decreases or remains the same as when exposure
was terminated. Thus in the rat, bladder cancer risk
does not rise after stopping exposure to 2-AAF (25);
similarly, in man, the risk of developing lung cancer
decreases within a few years of stopping smoking
because cigarette smoke, though it does have some
initiating activity, is predominantly a later-stage
carcinogen for the lung (9, 89). Cigarette smoking
also approximately doubles the risk of bladder can-
cer in man (87), but no experimental evidence is
available from work with animal models to indicate
whether cigarette smoke affects predominantly the
first stage or the later stages of the biogenesis of
bladder cancer.
With the mouse skin model it has proved possible
to separate late stage carcinogens into promoters,
which work at the second stage, and still later-stage
carcinogens which are capable of advancing the
progress of cancer development in cells which have
already been subjected to two or more events in the
right time sequence. In the bladder, no such rigid
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distinction can be made as yet, although available
evidence suggests that saccharin and some other
compounds may be promoters, whereas local irrita-
tion from calculi, or S.haematobium ova and some
dietary factors such as vitamin A deficiency, may be
later stage carcinogens. So far, no unequivocal cellu-
lar, subcellular or biochemical marker is available
which will unequivocally distinguish the action of a
promoter from that of a later stage carcinogen in
the urinary bladder. In terms of human cancer prev-
alence, the distinction between early and late-stage
carcinogens is clearly useful because of the immedi-
ate effect that removal of late stage carcinogens has
on the subsequent relative risk of developing can-
cer. It is debatable, however, whether emphasis on
narrowly defined second-stage promoters to the ex-
clusion of factors affecting the later stages of carci-
nogenesis, will prove to be equally rewarding. All
late-stage carcinogens have the potential to acceler-
ate tumor development and lower the age at which
cancer becomes symptomatic. It is thus important
to attempt to reduce exposure not just to second-
stage, skin-type promoters but to all factors acting
at later stages in the carcinogenic process.
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